What is the difference between metoprolol tartrate and succinate
Pro Research Analysisby 
Searched over 200M research papers
Differences Between Metoprolol Tartrate and Metoprolol Succinate
Introduction to Metoprolol Variants
Metoprolol is a beta-blocker commonly used to treat various cardiovascular conditions, including hypertension, angina, and heart failure. It is available in two primary formulations: metoprolol tartrate (MT) and metoprolol succinate (MS). While both forms are effective, they have distinct pharmacokinetic properties and clinical applications.
Pharmacokinetic Properties
Absorption and Release Mechanisms
Metoprolol tartrate is an immediate-release formulation, typically administered twice daily. In contrast, metoprolol succinate is an extended-release formulation, designed for once-daily dosing. This difference in release mechanisms affects the drug's absorption and duration of action. Metoprolol succinate provides a more stable plasma concentration over 24 hours, which can be beneficial for maintaining consistent therapeutic effects 147.
Solid-State Behavior
The solid-state structures of MT and MS also differ. MS exhibits a slightly greater cohesive energy and undergoes reversible anisotropic lattice expansion/contraction upon temperature changes. In contrast, MT expands/contracts isotropically and forms an amorphous solid upon cooling from the melt, taking several days to revert to its crystalline form 29. These differences can influence the drug's stability and shelf life.
Clinical Efficacy and Safety
Heart Failure Management
Both MT and MS have been shown to produce similar hemodynamic and clinical effects in patients with congestive heart failure. Studies indicate that both formulations improve cardiac function, exercise capacity, and hemodynamic parameters without significant differences in adverse effects 149. However, MS may offer advantages in terms of more rapid initiation and ease of dosing due to its once-daily administration .
Chronic Obstructive Pulmonary Disease (COPD) and Heart Failure
In patients with COPD complicating chronic heart failure, MS has been found to be more effective in improving cardiac function compared to MT, although both formulations have similar safety profiles . This suggests that MS might be preferable in patients with coexisting pulmonary conditions.
Vasospastic Angina
For vasospastic angina, MS has shown a significant advantage in reducing the incidence of clinically significant angina attacks compared to MT. However, there were no significant differences in the rates of cardiovascular mortality, myocardial infarction, or stroke between the two formulations .
Acute Myocardial Infarction
In the context of acute myocardial infarction, both MT and MS effectively reduce heart rates. However, there is no significant difference in the degree and trend of heart rate reduction between the two formulations over the first 72 hours of treatment .
Hypertension
Both MT and MS are effective in managing mild hypertension, with no significant differences in achieving target blood pressure goals. However, MS has been noted to significantly reduce the morning blood pressure peak and increase heart rate variability, which may offer additional benefits in blood pressure management .
Conclusion
While metoprolol tartrate and metoprolol succinate are both effective beta-blockers, they have distinct pharmacokinetic properties and clinical applications. Metoprolol succinate's extended-release formulation offers advantages in dosing convenience and maintaining stable plasma levels, which can be particularly beneficial in chronic conditions like heart failure and hypertension. However, both formulations are generally comparable in terms of efficacy and safety across various cardiovascular conditions.
Sources and full results
Most relevant research papers on this topic